Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Total Equity

Last Annual Value

6.43M

3-Year CAGR

-18%

5-Year CAGR

105%

10-Year CAGR

88%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Total Equity

NTRB · NASDAQ
CompanyTotal Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
6.43M
-0.0%-11.5%75.6% 
123.12M
-6.5%-5.2%N/A
86.51M
0.4%-16.1%50.4%
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
140.35M
-13.8%-12.2%9.0%
112.52M
-2.4%N/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
159.21M
-2.2%-12.1%-6.3%
18.56M
13.9%-11.8%N/A
23.63M
-25.8%-16.1%38.5%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
87.80M
14.9%-14.1%16.7%
IMA logo
ImageneBio Inc
NASDAQ:IMA
133.14M
-7.8%-8.5%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
-6.67M
N/AN/AN/A
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15